Microbot Medical Initiates Full Market Launch of LIBERTY Endovascular Robotic System in U.S.
Microbot Medical Initiates Full Market Launch of LIBERTY® Endovascular Robotic System in U.S.
Key Highlights for Investors
- Microbot Medical Inc. (NASDAQ: MBOT) has announced the commencement of its Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the United States.
- The launch follows a successful Limited Market Release (LMR), with adoption across multiple prominent U.S. healthcare systems, including Emory Healthcare and Tampa General Hospital.
- LIBERTY is the first and only FDA-cleared, single-use, remotely operated robotic system for endovascular procedures, representing a new category in the field.
- The launch will be formally showcased at the Society of Interventional Radiology (SIR) Annual Scientific Meeting in Toronto (April 11-15).
Details of the Announcement
Microbot Medical’s LIBERTY system has demonstrated rapid market adoption and scalability, having been incorporated into healthcare networks with dozens of hospitals, including globally recognized institutions. This strong uptake is seen as a validation of the system’s clinical value and commercial potential.
The LIBERTY system has been used commercially across a wide spectrum of endovascular procedures, such as:
- Prostate Artery Embolization (PAE)
- Uterine Fibroid Embolization (UFE)
- Genicular Artery Embolization (GAE)
- Y90 mapping and deliveries
- Peripheral arterial interventions
Physicians have praised LIBERTY for its precision, short learning curve, fast setup, and compatibility with preferred wires and catheters. The system also demonstrates potential efficiency improvements by reducing both procedure times and the number of instruments required.
Strategic Expansion and Commercialization
In preparation for the FMR, Microbot Medical has expanded its commercial team and sales coverage, doubling its sales territories from four to eight, with a target of reaching 12 territories by the end of 2026. The company is focused on leveraging existing customer enthusiasm, as many users have expanded LIBERTY’s use to multiple procedures and additional hospital sites within their networks.
According to Chairman, President & CEO Harel Godot, the rapid adoption during the LMR indicates a shorter sales cycle compared to traditional surgical robots, which is a key differentiator and could accelerate further market penetration.
Market and Regulatory Tailwinds
The SIR conference is a pivotal opportunity for Microbot Medical, as it represents the company’s primary target market in the U.S. and brings together over 8,000 professionals in interventional radiology. The company plans to engage directly with attendees, demonstrate the LIBERTY system at booth #423, and educate physicians on its full capabilities to accelerate adoption.
Importantly, recent guidelines from SIR and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), as well as a new American Medical Association (AMA) policy, emphasize enhanced protections for healthcare professionals against occupational radiation exposure. LIBERTY’s remote operation feature directly addresses these updated safety and ergonomic concerns, positioning the system as a timely solution to industry needs.
About Microbot Medical
Microbot Medical Inc. is a commercial-stage medical device company focused on advancing endovascular procedures through innovative robotic technology. The company’s LIBERTY system is the world’s first FDA-cleared, single-use, remotely operated robotic solution for peripheral endovascular procedures. Backed by a robust intellectual property portfolio, Microbot is committed to driving the future of endovascular care.
Implications for Shareholders
- The transition to full commercial launch and the system’s rapid adoption in prestigious hospital systems could be significant catalysts for share price appreciation.
- LIBERTY’s unique FDA-cleared status, single-use design, and remote operation could set a new standard in the industry, potentially increasing the company’s market share and revenue growth.
- The company’s expansion of its commercial team and sales footprint demonstrates a commitment to scaling its business and capitalizing on early market momentum.
- Recent industry guidelines and policies increasing demand for radiation safety may further drive adoption of LIBERTY, creating additional tailwinds for growth.
Forward-Looking Statements and Risks
Investors should note that statements regarding future financial results, product adoption, and growth prospects are forward-looking and subject to risks and uncertainties. These include market conditions, commercialization challenges, regulatory pathways, geopolitical factors, and intellectual property matters. For further information, investors are encouraged to review the company’s filings with the SEC.
Contact Information
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with a financial advisor before making any investment decisions. The information provided herein is based on company filings and announcements and may be subject to change or updates.
View Microbot Medical Inc. Historical chart here
